Ningbo Joyson Electronic Corp. (SHA:600699)

Verve Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	56,723	55,424	55,317	49,793	45,021	47,054
Other Revenue	439.27	439.27	411.76	-	649.03	836.33
Revenue	57,162	55,864	55,728	49,793	45,670	47,890
Revenue Growth (YoY)	2.47%	0.24%	11.92%	9.03%	-4.63%	-22.38%
Cost of Revenue	47,980	47,253	48,020	44,108	40,682	41,839
Gross Profit	9,182	8,611	7,709	5,686	4,989	6,050
Selling, General & Admin	3,051	2,872	2,682	2,851	3,574	3,899
Research & Development	2,683	2,492	2,445	2,058	2,246	2,177
Other Operating Expenses	46.58	40.19	66.48	141.06	122.21	133.85
Operating Expenses	5,823	5,437	5,228	5,034	5,978	6,318
Operating Income	3,360	3,173	2,481	651.52	-989.9	-267.57
Interest Expense	-1,138	-1,130	-1,121	-932.11	-1,026	-1,141
Interest & Investment Income	321.28	356.36	280.54	219.47	251.72	1,892
Currency Exchange Gain (Loss)	216.83	216.83	179.63	381.91	-22.67	-14.95
Other Non Operating Income (Expenses)	-91.98	-18.77	-25.64	-22.32	-13.06	-10.12
EBT Excluding Unusual Items	2,668	2,597	1,794	298.47	-1,800	458.16
Merger & Restructuring Charges	-621.37	-621.37	-239.67	-233.1	-229.03	-
Impairment of Goodwill	-	-	-	-	-2,019	-
Gain (Loss) on Sale of Investments	41.66	36.87	157.13	101.78	63.19	-3.01
Gain (Loss) on Sale of Assets	1.1	3.35	12.41	-1.76	-23.83	-63.83
Asset Writedown	-58.5	-54.76	-25.53	-4.54	-	-0.04
Other Unusual Items	36.63	34.2	63.46	318.97	119.76	102.57
Pretax Income	2,068	1,996	1,762	479.82	-3,889	493.84
Income Tax Expense	718.64	669.47	522.19	246.56	646.19	290.01
Earnings From Continuing Operations	1,349	1,326	1,240	233.26	-4,535	203.83
Minority Interest in Earnings	-354.79	-365.81	-156.9	160.92	782.17	412.34
Net Income	994.42	960.47	1,083	394.18	-3,753	616.17
Net Income to Common	994.42	960.47	1,083	394.18	-3,753	616.17
Net Income Growth	-16.40%	-11.33%	174.79%	-	-	-34.45%
Shares Outstanding (Basic)	1,398	1,392	1,389	1,359	1,370	1,257
Shares Outstanding (Diluted)	1,398	1,392	1,389	1,359	1,370	1,257
Shares Change (YoY)	-0.36%	0.24%	2.17%	-0.77%	8.93%	3.00%
EPS (Basic)	0.71	0.69	0.78	0.29	-2.74	0.49
EPS (Diluted)	0.71	0.69	0.78	0.29	-2.74	0.49
EPS Growth	-16.10%	-11.54%	168.97%	-	-	-36.36%
Free Cash Flow	1,717	1,389	158.59	-1,134	-983.7	-347.83
Free Cash Flow Per Share	1.23	1.00	0.11	-0.83	-0.72	-0.28
Dividend Per Share	0.260	0.260	0.260	0.100	-	0.150
Dividend Growth	-	-	160.00%	-	-	114.29%
Gross Margin	16.06%	15.41%	13.83%	11.42%	10.92%	12.63%
Operating Margin	5.88%	5.68%	4.45%	1.31%	-2.17%	-0.56%
Profit Margin	1.74%	1.72%	1.94%	0.79%	-8.22%	1.29%
Free Cash Flow Margin	3.00%	2.49%	0.29%	-2.28%	-2.15%	-0.73%
EBITDA	4,997	5,026	5,197	3,351	1,730	2,671
EBITDA Margin	8.74%	9.00%	9.33%	6.73%	3.79%	5.58%
D&A For EBITDA	1,637	1,853	2,717	2,700	2,720	2,939
EBIT	3,360	3,173	2,481	651.52	-989.9	-267.57
EBIT Margin	5.88%	5.68%	4.45%	1.31%	-2.17%	-0.56%
Effective Tax Rate	34.75%	33.55%	29.63%	51.39%	-	58.73%
Revenue as Reported	57,162	55,864	55,728	49,793	45,670	47,890
Advertising Expenses	-	15.52	15.38	11.55	11.97	6.68

Source: S&P Global Market Intelligence. Standard template. Financial Sources.